Format
Sort by

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 311

1.

CtBP1 associates metabolic syndrome and breast carcinogenesis targeting multiple miRNAs.

De Luca P, Dalton GN, Scalise GD, Moiola CP, Porretti J, Massillo C, Kordon E, Gardner K, Zalazar F, Flumian C, Todaro L, Vazquez ES, Meiss R, De Siervi A.

Oncotarget. 2016 Apr 5;7(14):18798-811. doi: 10.18632/oncotarget.7711.

2.

Tuberculosis: medico-legal aspects.

Vetrugno G, De-Giorgio F, D'Alessandro F, Scafetta I, Berloco F, Buonsenso D, Abbate F, Scalise G, Pascali VL, Valentini P.

Mediterr J Hematol Infect Dis. 2014 Apr 19;6(1):e2014033. doi: 10.4084/MJHID.2014.033. Review.

3.

Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy.

Antonucci G, Mazzotta F, Angeletti C, Girardi E, Puoti M, De Stefano G, Grossi P, Petrosillo N, Pagano G, Cassola G, Orani A, Sagnelli C, Armignacco O, Sagnelli E; Coorte Epatiti B SIMIT/COESI-B (HIV) Group..

BMC Res Notes. 2013 Apr 17;6:153. doi: 10.1186/1756-0500-6-153.

4.

Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts.

Nozza S, Canducci F, Galli L, Cozzi-Lepri A, Capobianchi MR, Ceresola ER, Narciso P, Libertone R, Castelli P, Moioli M, D'Arminio Monforte A, Castagna A; ICONA Foundation..

J Antimicrob Chemother. 2012 May;67(5):1224-7. doi: 10.1093/jac/dkr600.

PMID:
22298348
5.

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.

Torti C, d'Arminio-Monforte A, Pozniak AL, Lapadula G, Cologni G, Antinori A, De Luca A, Mussini C, Castagna A, Cicconi P, Minoli L, Costantini A, Carosi G, Liang H, Cesana BM; MASTER, Chelsea & Westminster, ICONA, Modena and S. Raffaele HIV Cohorts..

BMC Infect Dis. 2011 Jan 25;11:23. doi: 10.1186/1471-2334-11-23.

6.

Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures.

Trotta MP, Cozzi-Lepri A, Ammassari A, Vecchiet J, Cassola G, Caramello P, Vullo V, Soscia F, Chiodera A, Ladisa N, Abeli C, Cauda R, Buonuomi AR, Antinori A, d'Arminio Monforte A; ICONA Foundation Study..

Clin Infect Dis. 2010 Aug 15;51(4):456-64. doi: 10.1086/655151.

PMID:
20597690
7.

Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure.

Tordato F, Cozzi Lepri A, Cicconi P, De Luca A, Antinori A, Colangeli V, Castagna A, Nasta P, Ladisa N, Giacometti A, d'Arminio Monforte A, Gori A; ICONA Foundation Study Group..

HIV Med. 2011 Jan;12(1):4-13. doi: 10.1111/j.1468-1293.2010.00855.x.

8.

Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.

Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG; DAD study group..

Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501. doi: 10.1097/HJR.0b013e328336a150.

PMID:
20543702
9.

[Durability and tolerability of long-term nevirapine-based HAART].

Giacometti A, Butini L, Cirioni O, Costantini A, Montroni M, Scalise G.

Infez Med. 2010 Mar;18(1):20-6. Italian.

10.

Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.

Baroncelli S, Villani P, Weimer LE, Ladisa N, Francisci D, Tommasi C, Vullo V, Preziosi R, Cicalini S, Cusato M, Galluzzo C, Floridia M, Regazzi M; ISS-NIA Group..

Ann Pharmacother. 2010 May;44(5):838-43. doi: 10.1345/aph.1M688.

PMID:
20371753
11.

Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program.

Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Barton R, Bijie H, Bille J, Chang SC, da Luz Martins M, Duse A, Dzierzanowska D, Ellis D, Finquelievich J, Gould I, Gur D, Hoosen A, Lee K, Mallatova N, Mallie M, Peng NG, Petrikos G, Santiago A, Trupl J, VanDen Abeele AM, Wadula J, Zaidi M; Global Antifungal Surveillance Group..

Diagn Microbiol Infect Dis. 2010 Jun;67(2):162-71. doi: 10.1016/j.diagmicrobio.2010.01.002.

PMID:
20338711
12.

OpuC--an ABC transporter that is associated with Staphylococcus aureus pathogenesis.

Kiran MD, Akiyoshi DE, Giacometti A, Cirioni O, Scalise G, Balaban N.

Int J Artif Organs. 2009 Sep;32(9):600-10.

PMID:
19856269
13.

Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.

Cicconi P, Cozzi-Lepri A, Castagna A, Trecarichi EM, Antinori A, Gatti F, Cassola G, Sighinolfi L, Castelli P, d'Arminio Monforte A; ICoNA Foundation Study Group..

HIV Med. 2010 Feb;11(2):104-13. doi: 10.1111/j.1468-1293.2009.00750.x.

14.

Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ; ARTEMIS DISK Global Antifungal Surveillance Group..

Diagn Microbiol Infect Dis. 2009 Sep;65(1):27-34. doi: 10.1016/j.diagmicrobio.2009.05.007.

PMID:
19679232
15.

Anidulafungin in combination with amphotericin B against Aspergillus fumigatus.

Spreghini E, Orlando F, Santinelli A, Pisa E, Loretelli C, Manso E, Milici ME, Scalise G, Barchiesi F.

Antimicrob Agents Chemother. 2009 Sep;53(9):4035-9. doi: 10.1128/AAC.00659-09.

16.

In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes.

Simonetti O, Ganzetti G, Arzeni D, Campanati A, Marconi B, Silvestri C, Cirioni O, Gabrielli E, Lenci I, Kamysz W, Kamysz E, Giacometti A, Scalise G, Barchiesi F, Offidani A.

Peptides. 2009 Oct;30(10):1794-7. doi: 10.1016/j.peptides.2009.06.033.

PMID:
19591887
17.

Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients.

Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, Orani A, Moioli C, Rizzardini G, Uberti-Foppa C, Puoti M, Monforte AD; Hepa I.C.o.N.A the Icona Foundation Study Groups..

J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):574-81. doi: 10.1097/QAI.0b013e3181add592.

PMID:
19590432
18.

In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes.

Simonetti O, Arzeni D, Ganzetti G, Silvestri C, Cirioni O, Gabrielli E, Castelletti S, Kamysz W, Kamysz E, Scalise G, Offidani A, Barchiesi F.

Br J Dermatol. 2009 Aug;161(2):249-52. doi: 10.1111/j.1365-2133.2009.09166.x.

PMID:
19438437
19.

Therapeutic efficacy of buforin II and rifampin in a rat model of Acinetobacter baumannii sepsis.

Cirioni O, Silvestri C, Ghiselli R, Orlando F, Riva A, Gabrielli E, Mocchegiani F, Cianforlini N, Trombettoni MM, Saba V, Scalise G, Giacometti A.

Crit Care Med. 2009 Apr;37(4):1403-7. doi: 10.1097/CCM.0b013e31819c3e22.

PMID:
19318826
20.

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.

Antiretroviral Therapy Cohort Collaboration (ART-CC)., Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M.

Clin Infect Dis. 2009 Apr 15;48(8):1138-51. doi: 10.1086/597468.

Items per page

Supplemental Content

Loading ...
Support Center